Russom Mulugeta, Bahta Iyassu, Debesai Merhawi
National Medicines and Food Administration, Ministry of Health, Asmara, Eritrea.
Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, The Netherlands.
Drug Saf. 2021 Oct;44(10):1021-1032. doi: 10.1007/s40264-021-01102-x. Epub 2021 Sep 1.
Establishing a mature pharmacovigilance system in a low-income country is a challenge. Nevertheless, Eritrea, one such low-income country, was able to achieve a fully fledged pharmacovigilance system within a period of almost 9 years. In the last five years (2014-2019), the Eritrean Pharmacovigilance Centre has submitted, on average, 646 individual case safety reports (ICSRs) per million inhabitants per year to the World Health Organization (WHO) global database of ICSRs. As a result, Eritrea has been rated among the top reporting countries in Africa. The center has detected about 30 safety signals, achieved maturity level three on the WHO rapid benchmarking assessment, and gained huge political commitment. In the last few years, monitoring of product quality through the pharmacovigilance system found approximately 55 medical products that were either substandard or falsified and were subsequently recalled from the Eritrean market by the National Medicines and Food Administration. The aim of this article is to describe Eritrea's success stories, key strategies for success, challenges encountered, and lessons learned to share them with the international pharmacovigilance community and beyond.
在低收入国家建立成熟的药物警戒系统是一项挑战。然而,厄立特里亚这样一个低收入国家,在近9年的时间里建立起了一个完备的药物警戒系统。在过去五年(2014 - 2019年),厄立特里亚药物警戒中心平均每年每百万居民向世界卫生组织(WHO)的全球个例安全报告(ICSR)数据库提交646份个例安全报告。因此,厄立特里亚在非洲报告国家中名列前茅。该中心已发现约30个安全信号,在世卫组织快速基准评估中达到三级成熟水平,并获得了巨大的政治支持。在过去几年里,通过药物警戒系统对产品质量进行监测,发现约55种医疗产品不合格或为假药,随后被国家药品和食品管理局从厄立特里亚市场召回。本文旨在描述厄立特里亚的成功案例、成功的关键策略、遇到的挑战以及汲取的经验教训,以便与国际药物警戒界及其他方面分享。